You are here: Industry Insights > Imfinzi

News List

Imfinzi approved in EU to treat extensive-stage small cell lung cancer europeanpharmaceuticalreview
September 14, 2020
Imfinzi (durvalumab) has been approved by the European Commission as a first-line treatment for extensive-stage small cell lung cancer, with chemotherapy.
EU approves AstraZeneca’s Imfinzi for treatment of extensive-stage small cell lung cancer expresspharma
September 02, 2020
Imfinzi, in combination with etoposide and either carboplatin or cisplatin, is also approved in the US, Japan and several other countries for the treatment of ES-SCLC.
Imfinzi Granted FDA Priority Review for Less-Frequent, Fixed-Dose Use americanpharmaceuticalreview
August 21, 2020
AstraZeneca's Imfinzi (durvalumab) has received acceptance for its supplemental Biologics License Application (sBLA) and has also been granted Priority Review in the US for a new four-week, fixed-dose regimen for treatment in the approved indications ...
Priority review for Imfinzi's less-frequent dosing regimen pharmatimes
August 19, 2020
AstraZeneca's Imfinzi (durvalumab) has been granted a priority review in the US for a new four-week, fixed-dose regimen for treatment of non-small cell lung cancer (NSCLC) and bladder cancer.
Imfinzi Recommended for Approval by CHMP for Small Cell Lung Cancer americanpharmaceuticalreview
August 03, 2020
AstraZeneca’s Imfinzi (durvalumab) has been recommended for marketing authorization in the European Union (EU) for the 1st-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC) in combination with a choice of chemotherapies ...
Imfinzi shows sustained OS benefit in first-line ES-SCLC in CASPIAN trial pharmaceutical-business-review
June 03, 2020
Detailed results from an updated analysis of the Phase III CASPIAN trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin ...
FDA approves Imfinzi for extensive-stage SCLC pharmatimes
April 01, 2020
AstraZeneca has announced that Imfinzi (durvalumab) has been approved by the US Food and Drug Administration (FDA) as 1st-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC).
FDA approves AstraZeneca’s Imfinzi for small cell lung cancer pharmaceutical-technology
March 31, 2020
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Imfinzi (durvalumab) for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) in adults.
Imfinzi, tremelimumab combo flunks SCLC trial pharmatimes
March 19, 2020
AstraZeneca has released new high-level data from the final analysis of the Phase III CASPIAN trial, showing that the addition of the anti-CTLA4 antibody tremelimumab ...
Imfinzi Confirmed Sustained Overall Survival Benefit in Small Cell Lung Cancer Trial americanpharmaceuticalreview
March 18, 2020
High-level results from the final analysis of the Phase III CASPIAN trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice of standard-of-care (SoC) chemotherapies confirmed a sustained.

Previous page 1 2 3 4 5 Next page